Andrea Lobo,  —

The Pulmonary Hypertension Association (PHA) has launched a certificate program to provide advanced practice providers and allied health professionals with specialized training for diagnosis, treatment, and management of pulmonary hypertension (PH). Enrollment in the Pulmonary Hypertension Certificate Program’s first group, starting in June, is now open, the PHA…

Pulmonary hypertension (PH) is associated with an increased risk for sleep disorders, including obstructive sleep apnea, and structural brain changes at the genetic level, according to a recent study. These findings may help “develop new guidelines for the clinical management, personalized diagnosis, and treatment of PH, sleep disorder…

Insulin resistance or IR — a reduced response of body tissues to insulin, a hormone that regulates blood sugar levels — was found to correlate with disease severity in people with chronic thromboembolic pulmonary hypertension (CTEPH), according to a new study from researchers in China. Further, the team determined that…

Tenax Therapeutics said it will extend its Phase 3 clinical development of an oral form of levosimendan for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The company last year received $100 million in funding to help it complete an ongoing Phase 3 LEVEL trial…

Winrevair (sotatercept) is generally safe and effective for people with pulmonary arterial hypertension (PAH) when given in addition to their standard of care treatment, a pooled analysis of two clinical trials shows. Along with other benefits, the clinical studies — the Phase 2 PULSAR trial (NCT03496207) and…

LungFit PH, a device developed by Beyond Air for administering nitric oxide (NO) therapy, has received marketing approval from the Australian Therapeutic Goods Administration (TGA), which will allow the company to market the device as a Class IIb medical device. NO causes blood vessels to relax and widen, lowering…

Body weight-adjusted Uptravi (selexipag) dosing for children and adolescents with pulmonary arterial hypertension (PAH) resulted in exposure to the treatment’s active ingredient comparable to that in adults with PAH, a study showed. The study assessed the treatment’s pharmacokinetics — its…

The U.S. Food and Drug Administration (FDA) has provided Tiakis Biotech with advice for a planned Phase 2 clinical trial testing tiprelestat for pulmonary arterial hypertension (PAH). The ATHENA trial, which will assess the treatment’s safety and efficacy, is expected to enroll 90 patients, randomly assigned to receive…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ALG-801, Alivegen’s experimental treatment for pulmonary arterial hypertension (PAH). That designation aims to support the development of therapies for rare diseases, or those affecting fewer than 200,000 people in the U.S. It comes with certain…

Blood levels of angiopoietin-2, a marker of blood vessel damage, may help predict treatment response and outcomes in pulmonary arterial hypertension (PAH), according to a new study from researchers in the U.S. Levels of D-dimer, a marker of blood clot formation, were also increased in PAH patients, the study…

Indicators of high blood sugar levels, particularly stress hyperglycemia ratio (SHR), may predict clinical worsening in people with idiopathic pulmonary arterial hypertension, a study in China indicates. Clinical worsening was defined as the first occurrence of lung transplant, being rehospitalized due to heart failure, or death from any cause.

A new educational campaign aims to raise awareness of pulmonary arterial hypertension (PAH) symptoms, with the goal of accelerating diagnosis and improving treatment. The American Lung Association campaign has the support of Merck, which markets Winrevair (sotatercept), a medication approved this year in the U.S. and…